Search results for "Reno"

showing 10 items of 1031 documents

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter p…

2010

Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poor prognosis. First-line systemic treatments in advanced disease include mitotane, either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed the activity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavily pretreated advanced ACC patients. From 1998 to 2008, 28 patients with advanced ACC progressing after mitotane plus one or two systemic chemotherapy lines were enrolled. They received a combination of i.v. gemcitabine (800 mg/m2, on days 1 and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (2…

AdultMaleMucositisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAdrenocortical carcinomaSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhases of clinical researchDeoxycytidineGastroenterologyDrug Administration ScheduleCapecitabineEndocrinologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansMitotaneCapecitabineAgedChemotherapybusiness.industryLeukopeniaMiddle Agedmedicine.diseaseThrombocytopeniaGemcitabineAdrenal Cortex NeoplasmsGemcitabineRegimenTreatment OutcomeOncologyFluorouracilDisease ProgressionFemaleFluorouracilbusinessmedicine.drug
researchProduct

Basal opioid receptor binding is associated with differences in sensory perception in healthy human subjects: a [18F]diprenorphine PET study.

2009

The endogenous opioid system is involved in many body functions including pain processing and analgesia. To determine the role of basal opioid receptor availability in the brain in pain perception, twenty-three healthy subjects underwent positron emission tomography (PET) utilizing the subtype-nonselective opioid antagonist [(18)F]diprenorphine, quantitative sensory testing (QST) and the cold pressor test. Binding potentials (BPs) were calculated using a non-invasive reference tissue model and statistical parametric mapping was applied for t-statistical analysis on a voxelwise basis. We found that cold pain-sensitive subjects present a significantly lower BP in regions including the bilater…

AdultMalePain Thresholdmedicine.drug_classCognitive NeuroscienceSensationDiprenorphinePainInsular cortexYoung AdultOpioid receptorOpioid Receptor BindingPhysical StimulationmedicinePressureHumansEndogenous opioidBrain ChemistryBrainSomatosensory CortexMiddle AgedCold TemperatureNeurologyOpioidData Interpretation StatisticalPositron-Emission TomographySensory ThresholdsReceptors OpioidOrbitofrontal cortexPerceptionRadiopharmaceuticalsPsychologyDiprenorphineNeuroscienceOpioid antagonistmedicine.drugNeuroImage
researchProduct

Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.

2007

The aim of this study was to prospectively evaluate the frequency, indications, outcomes, and predictive factors associated with opioid switching, using a protocol that had been clinically applied and viewed as effective for many years. A prospective study was carried out on a cohort of consecutive cancer patients who were receiving opioids but had an unacceptable balance between analgesia and adverse effects, despite symptomatic treatment of side effects. The initial conversion ratio between opioids and routes was as follows (mg/day): oral morphine 100=intravenous morphine 33=transdermal fentanyl 1=intravenous fentanyl 1=oral methadone 20=intravenous methadone 16=oral oxycodone 70=transder…

AdultMalePalliative carePainFentanylpredictive factoropioid switchingMedicineHumansProspective StudiesOpioid peptideAdverse effectGeneral NursingAgedMorphinebusiness.industryPalliative Careacute palliative care unitMiddle AgedBuprenorphineAnalgesics OpioidFentanylAnesthesiology and Pain MedicineTreatment OutcomeOpioidAnesthesiaFemaleNeurology (clinical)businessCancer painOxycodoneMethadonemedicine.drugMethadoneJournal of pain and symptom management
researchProduct

Buprenorphine or procaine for pain relief in acute pancreatitis. A prospective randomized study.

2001

To assess the analgesic efficacy and side effects of buprenorphine and procaine in patients with acute pancreatitis.Forty patients (average age, 50 years; 23 male) with acute pancreatitis or an acute bout of a chronic pancreatitis were prospectively randomized to receive buprenorphine or procaine for pain relief. Both analgesics were administered as constant intravenous (i.v.) infusions and additional analgesics were given on demand. Pain scores were assessed on a visual analogue scale. Close clinical control and laboratory checks were performed during the three-day study period.Patients receiving buprenorphine were significantly less likely to demand additional analgesics (1 versus 14 pati…

AdultMaleRandomizationAnalgesicPainlaw.inventionProcaineRandomized controlled triallawmedicineHumansProspective StudiesProspective cohort studyInfusions IntravenousAgedPain MeasurementAnalgesicsbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseBuprenorphineAnalgesics OpioidPancreatitisAnesthesiaAcute DiseaseAcute pancreatitisPancreatitisFemalebusinessProcainemedicine.drugBuprenorphineScandinavian journal of gastroenterology
researchProduct

Beta-adrenergic stimulation enhances left ventricular diastolic performance in normal subjects.

1997

To determine the effects of beta-adrenergic stimulation on transmitral Doppler echocardiography flow characteristics of left ventricular diastolic filling, we studied 10 healthy volunteers aged 23-31 years (mean age, 26.6 years) during intravenous infusion of isoprenaline in consecutive steps of 0.1, 0.2, 0.4, 0.75, and 1.5 micrograms/min (each for 15 min). Saline control infusion was given in the same manner in a crossover and blinded protocol. Compared with the infusion of placebo, stepwise increasing doses of isoprenaline caused a dose-related increase in early and late diastolic filling velocities and velocity-time integrals, a lengthening of the acceleration time, and a shortening of t…

AdultMaleStress testingDiastoleHemodynamicsBlood PressureDoppler echocardiographyVentricular Function LeftDouble-Blind MethodHeart RateIsoprenalineHeart ratemedicineHumansInfusions IntravenousPharmacologyAnalysis of VarianceCross-Over Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryIsoproterenolAdrenergic beta-AgonistsEchocardiography DopplerBlood pressureAnesthesiaCirculatory systemCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of cardiovascular pharmacology
researchProduct

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers.

1992

Study objective The study was performed to evaluate the relative sensitivity of various noninvasive methods to detect and describe the systolic cardiovascular effects of stepwise increasing doses of isoproterenol: two-dimensional left ventricular echocardiography (main variable, ejection fraction), ACVF (attenuation compensated volume flow)–dual-beam Doppler echoaortography (time-averaged mean velocity), electrical impedance cardiography [(dZ/dtmax)/RZ index], and systolic time intervals from mechanocar-diography (PEP and QS2c). Methods Isoproterenol was administered by constant rate intravenous infusion in consecutive steps of 0.1, 0.2, 0.4, 0.75, and 1.5 µg/min (each for 15 minutes). Sali…

AdultMaleSystolemedicine.medical_treatmentCardiography ImpedanceCardiovascular SystemSensitivity and SpecificityAfterloadDouble-Blind MethodReference ValuesStatistical significanceIsoprenalineMedicineHumansPharmacology (medical)SystoleSalineAortaPharmacologyAnalysis of VarianceEjection fractionmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryIsoproterenolCrossover studyImpedance cardiographyEchocardiographyAnesthesiaHeart Function TestsbusinessBlood Flow Velocitymedicine.drugClinical pharmacology and therapeutics
researchProduct

Study of pituitary secretion in relation to retinopathy in patients with juvenile diabetes mellitus.

1981

Fifteen juvenile diabetic patients with normal eye fundus, 6 with non proliferative retinopathy, 5 with proliferative retinopathy and 5 healthy control subjects were studied in order to investigate pituitary function in relation to diabetic retinopathy. ACTH values at 08(00) and 18(00), hPRL and TSh secretion in response to 200 microgram TRH i.v., and GH secretion in response to 500 mg oral L-dopa were evaluated. In all diabetic subjects, 08(00) ACTH levels were lower than in controls. Basal hPRL, TSH and GH values of the diabetics did not differ from those of the controls. No significant differences were found in hPRL levels in response to TRH, whereas significantly lower TSH responses wer…

AdultMaleendocrine systemPituitary glandmedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismThyrotropin-releasing hormoneThyrotropinAdrenocorticotropic hormoneLevodopaEndocrinologyAdrenocorticotropic HormoneInternal medicineDiabetes mellitusInternal MedicineMedicineHumansThyrotropin-Releasing HormoneDiabetic Retinopathybusiness.industryGeneral MedicineDiabetic retinopathymedicine.diseaseGrowth hormone secretionProlactinProlactinKineticsmedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1Growth HormonePituitary GlandFemalebusinesshormones hormone substitutes and hormone antagonistsRetinopathyActa diabetologica latina
researchProduct

Effects of corticotropin-releasing hormone on respiratory parameters during sleep in normal men.

2009

Corticotropin-releasing hormone (CRH) is well-known to be a centrally acting respiratory stimulant after systemic application both in healthy subjects and in patients suffering from respiratory failure. In order to study the effects of CRH on sleep EEG and respiratory parameters during sleep, 14 healthy male volunteers were investigated in a single-blind placebo controlled design. After an adaptation night, polysomnography was performed during two successive nights between 23.00 hrs. and 7.00 hrs. During one night placebo was applied, on the other 50 μg ovine CRH was administered intravenously as a bolus every hour from 0.00 hrs. to 6.00 hrs. For the assessment of respiration, blood oxygen …

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneCorticotropin-Releasing HormoneEndocrinology Diabetes and MetabolismSleep REMPolysomnographyPlacebosCorticotropin-releasing hormoneEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodSleep and breathingInternal medicineInternal MedicinemedicineHumansRespiratory systemTidal volumeSlow-wave sleepmedicine.diagnostic_testbusiness.industryElectromyographyRespirationElectroencephalographyGeneral MedicineThoraxOxygenKineticsEndocrinologyRespiratory failureAnalepticAnesthesiabusinessSleephormones hormone substitutes and hormone antagonistsExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers

2000

Abstract To evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. Drugs were given as a single dose at 10:00 h for a period of 4 weeks each. Between days 21 and 28 of each treatment period, sleep EEG was registered for four consecutive nights from 23:00 to 07:00 h. During the last night, hormonal profiles for prolactin, growth hormone (GH), cortisol, corticotropin (ACTH), luteinizing hormone (LH), testosterone and melatonin w…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismSerotonin reuptake inhibitorPlaceboPlacebosMelatoninEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansBiological PsychiatryMelatoninCross-Over StudiesHuman Growth HormoneEndocrine and Autonomic SystemsElectroencephalographyLuteinizing HormoneParoxetineHormonesProlactinCircadian RhythmProlactinParoxetinePsychiatry and Mental healthEndocrinologySleep onsetReuptake inhibitorPsychologyLuteinizing hormoneSelective Serotonin Reuptake Inhibitorshormones hormone substitutes and hormone antagonistsmedicine.drugPsychoneuroendocrinology
researchProduct

Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans.

1987

Opiates stimulate the growth hormone and prolactin responses to stimuli in non-obese humans. Obese patients, however, show lowered growth hormone and prolactin responses and raised beta-endorphin levels. We therefore investigated the effect of the opiate antagonist naloxone on the stimulated growth hormone and prolactin secretions in a controlled double-blind study in obese patients. All patients received 200 micrograms TRH and 0.5 g/kg b.w. arginine together with 2 mg of naloxone or placebo i.v. in a randomized sequence. The TRH- and arginine-induced increases in prolactin and growth hormone were significantly greater after administration of naloxone (p less than 0.05). Naloxone also produ…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and Metabolismmedicine.medical_treatment(+)-NaloxoneArginineGlucagonEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansObesityOpioid peptideThyrotropin-Releasing HormoneTriiodothyroninebusiness.industryNaloxoneInsulinbeta-EndorphinAntagonistMiddle AgedProlactinProlactinEndocrinologyGrowth HormoneFemaleEndorphinsOpiatebusinesshormones hormone substitutes and hormone antagonistsJournal of endocrinological investigation
researchProduct